<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6471">
  <stage>Registered</stage>
  <submitdate>28/04/2017</submitdate>
  <approvaldate>28/04/2017</approvaldate>
  <nctid>NCT03136809</nctid>
  <trial_identification>
    <studytitle>ALS Treatment Extension Study</studytitle>
    <scientifictitle>A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CMD-2017-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Amyotrophic Lateral Sclerosis</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cu(II)ATSM

Experimental: Cu(II)ATSM - Cu(II)ATSM administered once daily


Treatment: drugs: Cu(II)ATSM
copper-containing synthetic small molecule

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tolerance of extended treatment - safety</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R) - efficacy</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score - efficacy</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in respiratory function by seated forced vital capacity (FVC) - efficacy</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in quality of life by ALSSQOL-R score - efficacy</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in respiratory function by sniff nasal pressure (SNP) test - efficacy</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Signed informed consent prior to initiation of any study-specific procedures and
             treatment

          -  Documented completion of protocol-specific assessments following completion of six
             28-day treatment cycles in study CMD-2016-001

          -  Principal Investigator considers the patient would benefit from continued treatment
             with Cu(II)ATSM

          -  Not taking riluzole or on the same (or lower) dose used during the CMD-2016-001 study

          -  Adequate bone marrow reserve, renal and liver function

          -  Women and men with partners of childbearing potential must take effective
             contraception while on study treatment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inability to swallow oral medications or presence of a gastrointestinal disorder
             (e.g.,malabsorption) deemed to jeopardize intestinal absorption of study drug

          -  Dependence on mechanical ventilation (invasive or non-invasive) for any part of day or
             night, where dependence is defined as being unable to lie flat (supine) without it,
             unable to sleep without it, or daytime use

          -  Dementia that may affect either outcome measures or patient understanding and/or
             compliance with study requirements and procedures

          -  Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>8/05/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/05/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Macquarie University - Sydney</hospital>
    <postcode>2109 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Collaborative Medicinal Development Pty Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Treatment extension study for ALS/MND patients who participated in phase 1 study
      CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the
      Investigator considers would benefit from continued CuATSM treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03136809</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dominic Rowe, MD</name>
      <address>Macquarie University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Kay Noel, PhD</name>
      <address />
      <phone>415 444 9602</phone>
      <fax />
      <email>Kay.Noel@ColMedDev.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>